Zydus Lifesciences bags USFDA nod for Ivermectin Cream for treatment of inflammatory lesions of rosacea
Ivermectin Cream is used for the treatment of inflammatory lesions of rosacea.
Ahmedabad: Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Ivermectin Cream, 1%. USRLD: Soolantra.
Ivermectin Cream is used for the treatment of inflammatory lesions of rosacea. The drug will be manufactured at the group's topical manufacturing facility at Ahmedabad, India.
Ivermectin Cream had annual sales of USD 176 million in the United States according to IQVIA data (IQVIA MAT June 2022).
The group now has 319 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Life Desidustat gets CDSCO panel nod to treat Anaemia in Kidney Patients
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.